Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.48 |
| ▸ | HASPIN | Q8TF76 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627019 | 0.94 | PIK3CA (0.47) | PIK3CAHASPINKCNH2FLT3KIT | |
| SCHEMBL625421 | 0.92 | PIK3CA (0.52) | PIK3CAHASPINKCNH2FLT3KIT | |
| SCHEMBL626122 | 0.91 | PIK3CA (0.45) | PIK3CAHASPINKCNH2FLT3KIT | |
| SCHEMBL627432 | 0.87 | RET (0.40) | PIK3CA | |
| SCHEMBL625407 | 0.85 | PIK3CA (0.45) | PIK3CAHASPIN | |
| SCHEMBL627308 | 0.85 | PIK3CA (0.49) | PIK3CAKCNH2 | |
| SCHEMBL624438 | 0.83 | PIK3CA (0.50) | PIK3CAHASPINKCNH2FLT3KIT | |
| SCHEMBL626245 | 0.83 | PIK3CA (0.46) | PIK3CAKCNH2 | |
| SCHEMBL627020 | 0.82 | RET (0.40) | PIK3CA | |
| SCHEMBL625131 | 0.80 | PIK3CA (0.49) | PIK3CAHASPINKCNH2FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |